Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

SB and Symphar join efforts to discover Lp(a)-lowering agents for atherosclerosis

Sep. 21, 2000

Niacin safely controls lipid disorders in diabetic patients

Sep. 20, 2000

Researchers identify new nuclear receptor targets for cholesterol control

Sep. 20, 2000

Newly issued patent covers series of guanylate cyclase activators designed by Aventis

Sep. 19, 2000

Guanidine-based Na+/H+ inhibitors synthesized and tested at Sumitomo

Sep. 19, 2000

Banyu's J-112287: a potent, selective and orally active ETA receptor antagonist

Sep. 19, 2000

Complement inhibitor TP-10 to enter phase IIb studies in infants

Sep. 18, 2000

Vasodilating and antiplatelet series designed at Lacer

Sep. 18, 2000

Cardioprotective agents from Pierre Fabre evaluated in several animal models

Sep. 18, 2000

Combination of doxazosin and amlodipine provides increased efficacy, improved tolerability

Sep. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...